TCR2 Therapeutics develops a novel class of T cell receptor (TCR)-based cellular therapies that harness the full signaling power of complete TCRs without HLA‑matching. Its proprietary multi-format TRuC™ platform reprograms the natural TCR complex to drive rapid cancer-cell killing with long persistence and low cytokine release. The company is advancing both solid tumor and blood cancer programs from this platform. Proceeds from the recent financing will advance two TRuC™-T cell programs through human proof-of-concept, including lead solid tumor candidate TC-210 targeting mesothelin. TCR2 also plans to expand its platform with dual-target TRuC™, immune cell enhancements and allogeneic technologies. The company is led by CEO Dr. Garry Menzel and is based in Cambridge, MA.

Total raised

$125M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2018